title: [Clinical development of S-1 (TS-1) for advanced gastric cancer].
abstract: The 5-FU plus cisplatin containing regimen like FP, ECF and DCF, is considered to be the most effective treatment for advanced gastric cancer in the United States, Europe, and Korea. In Japan, oral fluoropyrimidine S-1 (TS-1) is currently considered to be the first candidate as the standard drug for advanced gastric cancer. S-1 based combination therapies with other promising drugs like cisplatin, irinotecan and taxanes, are expected to yield good results. Above all, S-1+CDDP therapy showed a high efficacy and expected to be a standard therapy for advanced gastric cancer. Two large phase III studies, JCOG 9912 5-FU vs S-1 vs CPT-11 +CDDP and S-1 vs S-1+CDDP, are now on going to establish an acceptable frontline standard for patients with AGC. We therefore need to develop new agents and combination chemotherapy regimens to achieve a greater survival benefit in AGC.
authors.affiliation: Dept. of Gastroenterology and G I Oncology, Kitasato University School of Medicine, Sagamihara, Japan.
authors.forename: Koizumi
authors.initials: K
authors.lastname: Wasaburo
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tanabe
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Higuchi
authors.forename: Toru
authors.initials: T
authors.lastname: Sasaki
authors.forename: Norisuke
authors.initials: N
authors.lastname: Nakayama
authors.forename: Shizuka
authors.initials: S
authors.lastname: Mihara
authors.forename: Kento
authors.initials: K
authors.lastname: Nakatani
authors.forename: Ken
authors.initials: K
authors.lastname: Nishimura
authors.forename: Takuya
authors.initials: T
authors.lastname: Shimoda
authors.forename: Mizutomo
authors.initials: M
authors.lastname: Azuma
authors.forename: Chikatoshi
authors.initials: C
authors.lastname: Katada
authors.forename: Noboru
authors.initials: N
authors.lastname: Hanaoka
authors.forename: Akira
authors.initials: A
authors.lastname: Naruke
authors.forename: Takahiro
authors.initials: T
authors.lastname: Ryu
authors.forename: Kenji
authors.initials: K
authors.lastname: Ishido
authors.forename: Katsunori
authors.initials: K
authors.lastname: Saigenji
mesh_terms: D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D010094:Oxonic Acid / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage*
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin